Researchers are actively investigating how to overcome resistance to CDK4/6 inhibitors. A Phase 1b trial (TAKTIC) evaluated ipatasertib, an AKT pathway inhibitor, combined with endocrine therapyTreatments that reduce or block hormones that fuel certain cancers.Click for full explanation → and palbociclib in patients with treatment-refractory HR+/HER2A protein that promotes cell growth — overexpressed in some breast and stomach cancers.Click for full explanation →-negative metastatic disease. A Phase 3 trial (NCT04305496) compared capivasertib plus fulvestrant against placebo plus fulvestrant in locally advanced or metastatic HR+/HER2A protein that promotes cell growth — overexpressed in some breast and stomach cancers.Click for full explanation →-negative breast cancer. In HER2A protein that promotes cell growth — overexpressed in some breast and stomach cancers.Click for full explanation →-positive disease, a Phase 3 study (NCT05894239) is examining inavolisib combined with a pertuzumab-trastuzumab fixed-dose combination in PIK3CA-mutated HER2A protein that promotes cell growth — overexpressed in some breast and stomach cancers.Click for full explanation →-positive metastatic breast cancer. For TNBC, a Phase 3 trial (NCT06103864) is testing datopotamab deruxtecan (Dato-DXd) with or without durvalumab against chemotherapyDrugs that kill rapidly dividing cells, including cancer cells.Click for full explanation → plus pembrolizumab in PD-L1-positive metastatic or locally recurrent disease. Another Phase 3 study (ASCENT-05, NCT05633654) is evaluating sacituzumab govitecan plus pembrolizumab versus capecitabine for TNBC with residual invasive disease after surgery and neoadjuvant therapy. In early HR+ disease, a Phase 3b trial (NCT05827081) is examining ribociclib combined with endocrine therapyTreatments that reduce or block hormones that fuel certain cancers.Click for full explanation →. A pooled analysis from five randomized trials found that omitting axillary lymph node surgery reduces surgical morbidity without compromising survival, though it also limits staging data that determines CDK4/6 inhibitor eligibility. A Phase 3 trial (NCT06058377) is adding durvalumab to standard chemotherapyDrugs that kill rapidly dividing cells, including cancer cells.Click for full explanation → for Stage II-III breast cancer. Novel radiopharmaceutical approaches, including lutetium-177-labeled NeoB targeting the gastrin-releasing peptide receptor combined with ribociclib and fulvestrant (NCT05870579), are in Phase 1 testing.
Where the evidence stands
CDK4/6 inhibitors combined with endocrine therapyTreatments that reduce or block hormones that fuel certain cancers.Click for full explanation → have the strongest evidence base in HR+/HER2A protein that promotes cell growth — overexpressed in some breast and stomach cancers.Click for full explanation →-negative advanced breast cancer, supported by multiple Phase 3 trials and meta-analysesA statistical method that combines results from multiple studies for a stronger conclusion.Click for full explanation → confirming improvements in progression-free and overall survivalThe percentage of patients still alive after a set period — a key clinical trial endpoint.Click for full explanation →. HER2A protein that promotes cell growth — overexpressed in some breast and stomach cancers.Click for full explanation →-directed therapies, particularly trastuzumab deruxtecan, have Phase 3 data in both HER2A protein that promotes cell growth — overexpressed in some breast and stomach cancers.Click for full explanation →-positive and HER2A protein that promotes cell growth — overexpressed in some breast and stomach cancers.Click for full explanation →-low settings. ImmunotherapyTreatments that use the body's immune system to fight cancer.Click for full explanation → with pembrolizumab for TNBC is supported by Phase 3 evidence. AKT pathway inhibitors such as capivasertib are approved in select patients, while newer agents like inavolisib are in ongoing Phase 3 evaluation. Novel antibody-drug conjugates such as datopotamab deruxtecan are now in Phase 3 testing. De-escalation of axillary surgery is supported by pooled trial data, but its interaction with treatment eligibility decisions is still being worked out. Radiopharmaceutical strategies remain early-stage.
What this means for people affected
Breast cancer treatment options have expanded substantially across all major subtypes, and treatment selection depends heavily on tumor biology, molecular markers, and prior therapy history. Hormone receptor-positive disease has multiple targeted options that extend remission in advanced settings. HER2A protein that promotes cell growth — overexpressed in some breast and stomach cancers.Click for full explanation →-positive disease has highly effective antibody-drug conjugates available. TNBC, historically the hardest subtype to treat, now has immunotherapyTreatments that use the body's immune system to fight cancer.Click for full explanation → and newer targeted agents. The active research pipeline addresses resistance to established treatments, explores ways to reduce surgical burden, and tests new drug combinations, suggesting the landscape will continue to evolve.
Last updated May 4, 2026
Recent research findings
Understanding evidence levels▼
PreclinicalLab or cell studies — no human data yet.
Animal StudyResults in animals only — may not apply to humans.
Phase 1 TrialFirst-in-human safety testing in small groups.
Phase 2 TrialEarly effectiveness testing in a larger group.
Phase 3 TrialLarge controlled trial — the strongest trial evidence.
Observational StudyPatterns observed in populations — not a controlled trial.
ReviewSummary analysis of multiple existing studies.
Meta-AnalysisStatistical pooling of results from multiple studies.
Observational StudyPatterns observed in populations over time, not a controlled experiment.Published: August 15, 2026
Breast Cancer Patients' Acupuncture Adherence Linked to Several Factors
Researchers looked at why some breast cancer patients don't complete their acupuncture regimens. They found that non-White patients, those with advanced cancer, smokers, and those with anxiety were less likely to finish their treatments. The study suggests that these factors might be barriers to using acupuncture.
Why it matters: This finding highlights the importance of understanding why patients may not stick to complementary therapies like acupuncture.
Observational StudyPatterns observed in populations over time, not a controlled experiment.Published: August 14, 2026
Wait Times for Breast Cancer Treatment at Christchurch Hospital
Researchers looked at how long it took patients to get breast cancer radiation treatment at Christchurch Hospital. They found that wait times increased over time, but temporarily decreased during the COVID-19 lockdown. The exact reasons for the increase are unclear.
Why it matters: This study highlights the importance of minimizing delays in cancer treatment to reduce the risk of recurrence.
◆ Notable findingA noteworthy finding, often from later-stage research, but below the higher significance thresholds.Phase 3 TrialLarge controlled trial comparing treatments. The strongest level of trial evidence.Published: August 14, 2026
Rehabilitation Program for Breast Cancer Survivors Raises Questions
Researchers looked at the effects of a rehabilitation program called ReMAP on breast cancer survivors' mobility. They found some promising results, but more information is needed to fully understand the program's benefits. The study's findings are based on a small group of participants.
Why it matters: This study's findings could help inform future research on rehabilitation programs for breast cancer survivors.
Clarification is needed regarding participant accounting, the intention-to-treat analysis, the clinical interpretation of the Timed Up and Go outcome, control-group exposure, and the proposed mechanism linking movement quality to functional mobility.
Lab StudyLaboratory experiments on cells or tissue. No human or animal data.Published: August 14, 2026
New Peptide Materials Show Promise Against Resistant Infections and Cancer
Researchers created two new peptide materials that can fight off antibiotic-resistant bacteria and cancer cells. In lab experiments, these materials showed strong antibacterial activity and were effective against a type of aggressive breast cancer. The results suggest a potential new class of materials for treating infections and cancer.
Why it matters: This finding could lead to the development of new treatments for infections and cancer that are resistant to current therapies.
Efficacy
One of these peptide amphiphiles demonstrates a significant anticancer efficacy (with IC value of 6.9 µM) against human TNBC cells.
This study was conducted in a lab setting and has not been tested in humans.
Lab StudyLaboratory experiments on cells or tissue. No human or animal data.Published: August 14, 2026
New Compound Targets Breast Cancer Cells
Researchers created a new compound that targets breast cancer cells by using a sugar molecule to deliver a cancer-fighting agent. In lab experiments, this compound showed promise in killing cancer cells and stopping them from growing. However, more research is needed to confirm these findings.
Why it matters: This finding could lead to the development of new treatments for breast cancer that are more targeted and effective.
Efficacy
The CG ligand showed the highest potency with an IC₅₀ value of 7.51 ± 0.12 μg/mL or 14.2 μM.
Early-stage research, conducted in a lab setting using breast cancer cells.
Observational StudyPatterns observed in populations over time, not a controlled experiment.Published: August 14, 2026
Rare Case of Breast Cancer Metastasis Shows Importance of Re-Biopsy
Researchers reported a case of a woman with breast cancer who developed skin metastases 9 months after surgery. The cancer changed its type, making treatment more challenging. A biopsy was crucial to understand the new type of cancer.
Why it matters: This case highlights the importance of re-biopsy in patients with breast cancer who develop metastases, as the cancer type can change over time.
Observational StudyPatterns observed in populations over time, not a controlled experiment.Published: August 14, 2026
Androgen Receptor May Help Predict Cancer Outcomes in Some Patients
Researchers studied how androgen receptor expression affects breast cancer patients who received chemotherapyDrugs that kill rapidly dividing cells, including cancer cells.Click for full explanation → before surgery. They found that moderate-to-strong androgen receptor expression might be linked to better outcomes, especially in patients with incomplete cancer response to treatment.
Why it matters: This finding could help doctors better understand breast cancer and make more informed treatment decisions.
Efficacy
Moderate-to-strong AR expression was associated with a significantly lower recurrence risk (hazard ratio [HR] = 0.384, 95% CI: 0.160-0.918, P = .031).
The study had a relatively small sample size of 132 patients.
Lab StudyLaboratory experiments on cells or tissue. No human or animal data.Published: August 14, 2026
Combining Treatments May Help Fight Aggressive Breast Cancer
Researchers tested a combination of two treatments, sacituzumab govitecan and TRAIL agonists, in lab experiments and animal studies to see if they could work together to kill cancer cells in triple negative breast cancer. They found that the combination was effective in killing cancer cells in both lab experiments and animal studies. However, more research is needed to confirm these findings.
Why it matters: This finding could lead to new treatment options for patients with triple negative breast cancer.
This study was conducted in lab experiments and animal studies, and more research is needed to confirm these findings.
Lab StudyLaboratory experiments on cells or tissue. No human or animal data.Published: August 14, 2026
Lab Study Uncovers Potential Cancer Signaling Pathway
Researchers studied human breast cancer cells in lab experiments. They found that suppressing a specific signaling pathway may decrease cell growth and induce cell death, but the results are uncertain due to potential issues with the study.
Why it matters: This finding may be important for understanding how cancer cells grow and die, which could inform future research on cancer treatments.
The study's results are uncertain due to potential issues with the data and methods used.
ReviewSummary and analysis of existing published studies.Published: August 14, 2026
Plant Compounds May Help Fight Breast Cancer
Researchers looked at how plant-derived polyphenols affect breast cancer. They found that these compounds may slow cancer growth and reduce its spread, but more studies are needed to confirm this.
Why it matters: This finding could lead to new treatments or combinations of treatments for breast cancer.
Lab StudyLaboratory experiments on cells or tissue. No human or animal data.Published: August 14, 2026
Uric Acid May Contribute to Breast Cancer Growth
Researchers studied how uric acid affects breast cancer cells in lab experiments. They found that uric acid may help these cells grow and become more aggressive. However, more research is needed to understand the full impact.
Why it matters: This finding may help scientists better understand how breast cancer develops and grows, which could lead to new treatment ideas.
The study was conducted in a lab setting and more research is needed to confirm these findings in humans.
Observational StudyPatterns observed in populations over time, not a controlled experiment.Published: August 13, 2026
Using Contrast-Based Imaging May Reduce Breast Cancer Recurrence
Researchers looked at whether using contrast-based imaging at diagnosis helps identify breast cancer earlier. They found that women who had this imaging at diagnosis may have fewer breast cancer recurrences over five years. However, more research is needed to confirm these findings.
Why it matters: This finding may help doctors decide whether to use contrast-based imaging in the local staging of early breast cancer.
Efficacy
Patients who underwent CBI had significantly lower 5-year event rates among women with invasive cancer (adjusted HR 0.50, 95% CI 0.26-0.98, p = 0.043).
Testing Whether Hormone TherapyTreatments that reduce or block hormones that fuel certain cancers.Click for full explanation → With Ribociclib is as Effective as ChemotherapyDrugs that kill rapidly dividing cells, including cancer cells.Click for full explanation → Followed by Hormone TherapyTreatments that reduce or block hormones that fuel certain cancers.Click for full explanation → With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial
A Study Evaluating Adherence, Tolerability, and Patient Reported Outcomes of Giredestrant in Participants With ER+/HER2A protein that promotes cell growth — overexpressed in some breast and stomach cancers.Click for full explanation →- Early Breast Cancer Who Are Intolerant to Adjuvant Aromatase Inhibitor Therapy (novERA Breast Cancer)
A Phase I/II, Dose Finding and Optimization Study of [177Lu]Lu-NeoB in Combination With Capecitabine in Patients With GRPR+, ER+, HER2A protein that promotes cell growth — overexpressed in some breast and stomach cancers.Click for full explanation →- Metastatic Breast Cancer After Progression on Previous Endocrine TherapyTreatments that reduce or block hormones that fuel certain cancers.Click for full explanation → in Combination With a CDK4/6 Inhibitor.
Study of IEV407 as Single Agent or in Combination in Patients With Advanced HR+/HER2A protein that promotes cell growth — overexpressed in some breast and stomach cancers.Click for full explanation →- Breast Cancer
Adding an ImmunotherapyTreatments that use the body's immune system to fight cancer.Click for full explanation → Drug, MEDI4736 (Durvalumab), to the Usual ChemotherapyDrugs that kill rapidly dividing cells, including cancer cells.Click for full explanation → Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer
Minimally Interventional Study on Prevalence of Emerging ESR1 MutationsA change in DNA sequence that can drive cancer development.Click for full explanation → in Liquid Biopsy in Three Cohorts of Patients With Breast Cancer in Comparison With Patient's Baseline ESR1 MutationA change in DNA sequence that can drive cancer development.Click for full explanation → Status as Defined by Tissue Profiling.
